Literature DB >> 28457938

PARP inhibition protects mitochondria and reduces ROS production via PARP-1-ATF4-MKP-1-MAPK retrograde pathway.

Eniko Hocsak1, Viktor Szabo2, Nikoletta Kalman2, Csenge Antus2, Anna Cseh2, Katalin Sumegi2, Krisztian Eros2, Zoltan Hegedus3, Ferenc Gallyas4, Balazs Sumegi4, Boglarka Racz2.   

Abstract

Oxidative stress induces DNA breaks and PARP-1 activation which initiates mitochondrial reactive oxygen species (ROS) production and cell death through pathways not yet identified. Here, we show the mechanism by which PARP-1 influences these processes via PARylation of activating transcription factor-4 (ATF4) responsible for MAP kinase phosphatase-1 (MKP-1) expression and thereby regulates MAP kinases. PARP inhibitor, or silencing, of PARP induced MKP-1 expression by ATF4-dependent way, and inactivated JNK and p38 MAP kinases. Additionally, it induced ATF4 expression and binding to cAMP-response element (CRE) leading to MKP-1 expression and the inactivation of MAP kinases. In contrast, PARP-1 activation induced the PARylation of ATF4 and reduced its binding to CRE sequence in vitro. CHIP-qPCR analysis showed that PARP inhibitor increased the ATF4 occupancy at the initiation site of MKP-1. In oxidative stress, PARP inhibition reduced ROS-induced cell death, suppressed mitochondrial ROS production and protected mitochondrial membrane potential on an ATF4 and MKP-1 dependent way. Basically identical results were obtained in WRL-68, A-549 and T24/83 human cell lines indicating that the aforementioned mechanism can be universal. Here, we provide the first description of PARP-1-ATF4-MKP-1-JNK/p38 MAPK retrograde pathway, which is responsible for the regulation of mitochondrial integrity, ROS production and cell death in oxidative stress, and may represent a new mechanism of PARP in cancer therapy since cancer stem cells development is JNK-dependent.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ATF4; CREB; CREB2; Cancer; Dusp1; JNK; MKP-1; Oxidative stress; P38 MAPK; PARP-1 inhibition; ROS; Stem cells

Mesh:

Substances:

Year:  2017        PMID: 28457938     DOI: 10.1016/j.freeradbiomed.2017.04.018

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  27 in total

1.  Olaparib attenuates sepsis-induced acute multiple organ injury via ERK-mediated CD14 expression.

Authors:  Zhixia Chen; Yihui Chen; Xianwei Jin; Ying Liu; Zhenzhen Shao; Quan Li
Journal:  Exp Biol Med (Maywood)       Date:  2021-05-29

2.  AAV-Txnip prolongs cone survival and vision in mouse models of retinitis pigmentosa.

Authors:  Yunlu Xue; Sean K Wang; Parimal Rana; Emma R West; Christin M Hong; Helian Feng; David M Wu; Constance L Cepko
Journal:  Elife       Date:  2021-04-13       Impact factor: 8.713

Review 3.  PARP1 promoter links cell cycle progression with adaptation to oxidative environment.

Authors:  Julita Pietrzak; Corinne M Spickett; Tomasz Płoszaj; László Virág; Agnieszka Robaszkiewicz
Journal:  Redox Biol       Date:  2018-06-02       Impact factor: 11.799

Review 4.  Mitochondrial Protection by PARP Inhibition.

Authors:  Ferenc Gallyas; Balazs Sumegi
Journal:  Int J Mol Sci       Date:  2020-04-16       Impact factor: 5.923

5.  Eph A10-modified pH-sensitive liposomes loaded with novel triphenylphosphine-docetaxel conjugate possess hierarchical targetability and sufficient antitumor effect both in vitro and in vivo.

Authors:  Jiulong Zhang; Chunrong Yang; Shuang Pan; Menghao Shi; Jie Li; Haiyang Hu; Mingxi Qiao; Dawei Chen; Xiuli Zhao
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

6.  Cul4a as a New Interaction Protein of PARP1 Inhibits Oxidative Stress-Induced H9c2 Cell Apoptosis.

Authors:  Ning Ye; Naijin Zhang; Ying Zhang; Hao Qian; Boquan Wu; Yingxian Sun
Journal:  Oxid Med Cell Longev       Date:  2019-04-17       Impact factor: 6.543

Review 7.  Critical Roles of Dual-Specificity Phosphatases in Neuronal Proteostasis and Neurological Diseases.

Authors:  Noopur Bhore; Bo-Jeng Wang; Yun-Wen Chen; Yung-Feng Liao
Journal:  Int J Mol Sci       Date:  2017-09-13       Impact factor: 5.923

Review 8.  Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies.

Authors:  Pierpaola Davalli; Gaetano Marverti; Angela Lauriola; Domenico D'Arca
Journal:  Oxid Med Cell Longev       Date:  2018-03-27       Impact factor: 6.543

9.  MutT homolog 1 counteracts the effect of anti-neoplastic treatments in adult and pediatric glioblastoma cells.

Authors:  Shoshana Paglin; Amos Toren; Michal Yalon; Ziv Versano; Eitan Shany; Shany Freedman; Liron Tuval-Kochen; Moshe Leitner
Journal:  Oncotarget       Date:  2018-06-08

Review 10.  Role of the ISR-ATF4 pathway and its cross talk with Nrf2 in mitochondrial quality control.

Authors:  Shuya Kasai; Hiromi Yamazaki; Kunikazu Tanji; Máté János Engler; Tomoh Matsumiya; Ken Itoh
Journal:  J Clin Biochem Nutr       Date:  2018-09-15       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.